P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status.
作者： Susan Ashrafzadeh-Kian , Alicia Algeciras-Schimnich , Clifford R Jack , Ronald C Petersen , Val J Lowe
DOI: 10.1002/DAD2.12190
关键词:
摘要: Introduction Measurement of amyloid beta (Aβ40 and Aβ42) tau (phosphorylated [p-tau] total [t-tau]) in cerebrospinal fluid (CSF) can be utilized to differentiate clinical preclinical Alzheimer's disease dementia (AD) from other neurodegenerative processes. Methods CSF biomarkers were measured 150 participants the Mayo Clinic Study Aging Disease Research Center. P-tau/Aβ42 (Roche Elecsys, Fujirebio LUMIPULSE) Aβ42/40 (Fujirebio ratios compared one another positron emission tomography (PET) classification. Results Strong correlation was observed between LUMIPULSE p-tau/Aβ42 Aβ42/40, as well Elecsys (Spearman's ρ = -0.827, -0.858, 0.960, respectively). Concordance 96% both 97%. All had > 94% overall, positive, negative percent agreement with PET Discussion These data suggest that provide similar information assessment pathology.
sci-hub.st 参考文章(38)
Sebastian Palmqvist, Henrik Zetterberg, Kaj Blennow, Susanna Vestberg, Ulf Andreasson, David J. Brooks, Rikard Owenius, Douglas Hägerström, Per Wollmer, Lennart Minthon, Oskar Hansson, Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42: A Cross-Validation Study Against Amyloid Positron Emission Tomography. JAMA Neurology. ,vol. 71, pp. 1282- 1289 ,(2014) , 10.1001/JAMANEUROL.2014.1358
Rosebud O. Roberts, Yonas E. Geda, David S. Knopman, Ruth H. Cha, V. Shane Pankratz, Bradley F. Boeve, Robert J. Ivnik, Eric G. Tangalos, Ronald C. Petersen, Walter A. Rocca, The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics Neuroepidemiology. ,vol. 30, pp. 58- 69 ,(2008) , 10.1159/000115751
N. C. Fox, R. S. Black, S. Gilman, M. N. Rossor, S. G. Griffith, L. Jenkins, M. Koller, , Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. ,vol. 64, pp. 1563- 1572 ,(2005) , 10.1212/01.WNL.0000159743.08996.99
R. C. Petersen, R. O. Roberts, D. S. Knopman, Y. E. Geda, R. H. Cha, V. S. Pankratz, B. F. Boeve, E. G. Tangalos, R. J. Ivnik, W. A. Rocca, Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology. ,vol. 75, pp. 889- 897 ,(2010) , 10.1212/WNL.0B013E3181F11D85
Ira Driscoll, Juan C. Troncoso, Gay Rudow, Jitka Sojkova, Olga Pletnikova, Yun Zhou, Michael A. Kraut, Luigi Ferrucci, Chester A. Mathis, William E. Klunk, Richard J. O’Brien, Christos Davatzikos, Dean F. Wong, Susan M. Resnick, Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathologica. ,vol. 124, pp. 823- 831 ,(2012) , 10.1007/S00401-012-1025-1
E. N. Kapaki, G. P. Paraskevas, N. G. Tzerakis, C. Sfagos, A. Seretis, E. Kararizou, D. Vassilopoulos, Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease European Journal of Neurology. ,vol. 14, pp. 168- 173 ,(2007) , 10.1111/J.1468-1331.2006.01593.X
Andreas Leinenbach, Josef Pannee, Thomas Dülffer, Andreas Huber, Tobias Bittner, Ulf Andreasson, Johan Gobom, Henrik Zetterberg, Uwe Kobold, Erik Portelius, Kaj Blennow, Mass Spectrometry–Based Candidate Reference Measurement Procedure for Quantification of Amyloid-β in Cerebrospinal Fluid Clinical Chemistry. ,vol. 60, pp. 987- 994 ,(2014) , 10.1373/CLINCHEM.2013.220392
Tobias Bittner, Henrik Zetterberg, Charlotte E. Teunissen, Richard E. Ostlund, Michael Militello, Ulf Andreasson, Isabelle Hubeek, David Gibson, David C. Chu, Udo Eichenlaub, Peter Heiss, Uwe Kobold, Andreas Leinenbach, Kairat Madin, Ekaterina Manuilova, Christina Rabe, Kaj Blennow, Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid Alzheimers & Dementia. ,vol. 12, pp. 517- 526 ,(2016) , 10.1016/J.JALZ.2015.09.009
Guy M. McKhann, David S. Knopman, Howard Chertkow, Bradley T. Hyman, Clifford R. Jack, Claudia H. Kawas, William E. Klunk, Walter J. Koroshetz, Jennifer J. Manly, Richard Mayeux, Richard C. Mohs, John C. Morris, Martin N. Rossor, Philip Scheltens, Maria C. Carrillo, Bill Thies, Sandra Weintraub, Creighton H. Phelps, The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers & Dementia. ,vol. 7, pp. 263- 269 ,(2011) , 10.1016/J.JALZ.2011.03.005
Harald Hampel, Richard Frank, Karl Broich, Stefan J. Teipel, Russell G. Katz, John Hardy, Karl Herholz, Arun L. W. Bokde, Frank Jessen, Yvonne C. Hoessler, Wendy R. Sanhai, Henrik Zetterberg, Janet Woodcock, Kaj Blennow, Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives Nature Reviews Drug Discovery. ,vol. 9, pp. 560- 574 ,(2010) , 10.1038/NRD3115